Seizure prevalence, contributing factors, and prognostic factors in patients with leptomeningeal disease

Laura Ann Zima, Sunil Tulpule, Kaeli Samson, Nicole A Shonka

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: To determine seizure prevalence and contributing factors in patients with leptomeningeal disease (LMD). Methods: Authors performed a retrospective review of 79 consecutive patients with a diagnosis of LMD. Associations between categorical variables were assessed using Chi-Square tests or Fisher's Exact tests. Survival was plotted with Kaplan Meier curves. Variables with a log-rank p-value of <0.20 were entered into a Cox Proportional Hazard regression analysis. Results: Seizure prevalence in those with and without brain metastases was 22%. Of those who seized, 65% were admitted for this at least once while only one patient required intubation. Primary malignancy, type or route of chemotherapy administration, form of radiation therapy (craniospinal, focal, or whole brain), surgical treatment, location of LMD, and number of brain metastases did not influence seizure development. Only 13% of patients who never had seizures were on a prophylactic AED (anti-epileptic drug). In patients who had brain metastasis, there was no significant difference in prevalence of seizure before versus after LMD diagnosis suggesting that LMD does not significantly increase the risk of seizure compared to brain metastasis alone. A multivariate analysis revealed that while males trended toward inferior survival, only performance status and treatment with systemic chemotherapy showed a significant association with survival. Median survival time of patients after LMD diagnosis was four months. Conclusion: The prevalence of seizure in LMD patients is 22%. There were no statistically significant predisposing factors to seizure development. ECOG and use of systemic chemotherapy were found to be significant prognostic factors.

Original languageEnglish (US)
Pages (from-to)19-23
Number of pages5
JournalJournal of the Neurological Sciences
Volume403
DOIs
StatePublished - Aug 15 2019

Fingerprint

Seizures
Neoplasm Metastasis
Survival
Brain
Drug Therapy
Brain Diseases
Chi-Square Distribution
Intubation
Causality
Radiotherapy
Multivariate Analysis
Regression Analysis
Therapeutics
Pharmaceutical Preparations
Neoplasms

Keywords

  • Anti-epileptic drugs
  • Leptomeningeal carcinomatosis
  • Leptomeningeal disease
  • Seizure

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Seizure prevalence, contributing factors, and prognostic factors in patients with leptomeningeal disease. / Zima, Laura Ann; Tulpule, Sunil; Samson, Kaeli; Shonka, Nicole A.

In: Journal of the Neurological Sciences, Vol. 403, 15.08.2019, p. 19-23.

Research output: Contribution to journalArticle

@article{e5b86d1fb346417f8dd66488cd6382ad,
title = "Seizure prevalence, contributing factors, and prognostic factors in patients with leptomeningeal disease",
abstract = "Background: To determine seizure prevalence and contributing factors in patients with leptomeningeal disease (LMD). Methods: Authors performed a retrospective review of 79 consecutive patients with a diagnosis of LMD. Associations between categorical variables were assessed using Chi-Square tests or Fisher's Exact tests. Survival was plotted with Kaplan Meier curves. Variables with a log-rank p-value of <0.20 were entered into a Cox Proportional Hazard regression analysis. Results: Seizure prevalence in those with and without brain metastases was 22{\%}. Of those who seized, 65{\%} were admitted for this at least once while only one patient required intubation. Primary malignancy, type or route of chemotherapy administration, form of radiation therapy (craniospinal, focal, or whole brain), surgical treatment, location of LMD, and number of brain metastases did not influence seizure development. Only 13{\%} of patients who never had seizures were on a prophylactic AED (anti-epileptic drug). In patients who had brain metastasis, there was no significant difference in prevalence of seizure before versus after LMD diagnosis suggesting that LMD does not significantly increase the risk of seizure compared to brain metastasis alone. A multivariate analysis revealed that while males trended toward inferior survival, only performance status and treatment with systemic chemotherapy showed a significant association with survival. Median survival time of patients after LMD diagnosis was four months. Conclusion: The prevalence of seizure in LMD patients is 22{\%}. There were no statistically significant predisposing factors to seizure development. ECOG and use of systemic chemotherapy were found to be significant prognostic factors.",
keywords = "Anti-epileptic drugs, Leptomeningeal carcinomatosis, Leptomeningeal disease, Seizure",
author = "Zima, {Laura Ann} and Sunil Tulpule and Kaeli Samson and Shonka, {Nicole A}",
year = "2019",
month = "8",
day = "15",
doi = "10.1016/j.jns.2019.05.032",
language = "English (US)",
volume = "403",
pages = "19--23",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Seizure prevalence, contributing factors, and prognostic factors in patients with leptomeningeal disease

AU - Zima, Laura Ann

AU - Tulpule, Sunil

AU - Samson, Kaeli

AU - Shonka, Nicole A

PY - 2019/8/15

Y1 - 2019/8/15

N2 - Background: To determine seizure prevalence and contributing factors in patients with leptomeningeal disease (LMD). Methods: Authors performed a retrospective review of 79 consecutive patients with a diagnosis of LMD. Associations between categorical variables were assessed using Chi-Square tests or Fisher's Exact tests. Survival was plotted with Kaplan Meier curves. Variables with a log-rank p-value of <0.20 were entered into a Cox Proportional Hazard regression analysis. Results: Seizure prevalence in those with and without brain metastases was 22%. Of those who seized, 65% were admitted for this at least once while only one patient required intubation. Primary malignancy, type or route of chemotherapy administration, form of radiation therapy (craniospinal, focal, or whole brain), surgical treatment, location of LMD, and number of brain metastases did not influence seizure development. Only 13% of patients who never had seizures were on a prophylactic AED (anti-epileptic drug). In patients who had brain metastasis, there was no significant difference in prevalence of seizure before versus after LMD diagnosis suggesting that LMD does not significantly increase the risk of seizure compared to brain metastasis alone. A multivariate analysis revealed that while males trended toward inferior survival, only performance status and treatment with systemic chemotherapy showed a significant association with survival. Median survival time of patients after LMD diagnosis was four months. Conclusion: The prevalence of seizure in LMD patients is 22%. There were no statistically significant predisposing factors to seizure development. ECOG and use of systemic chemotherapy were found to be significant prognostic factors.

AB - Background: To determine seizure prevalence and contributing factors in patients with leptomeningeal disease (LMD). Methods: Authors performed a retrospective review of 79 consecutive patients with a diagnosis of LMD. Associations between categorical variables were assessed using Chi-Square tests or Fisher's Exact tests. Survival was plotted with Kaplan Meier curves. Variables with a log-rank p-value of <0.20 were entered into a Cox Proportional Hazard regression analysis. Results: Seizure prevalence in those with and without brain metastases was 22%. Of those who seized, 65% were admitted for this at least once while only one patient required intubation. Primary malignancy, type or route of chemotherapy administration, form of radiation therapy (craniospinal, focal, or whole brain), surgical treatment, location of LMD, and number of brain metastases did not influence seizure development. Only 13% of patients who never had seizures were on a prophylactic AED (anti-epileptic drug). In patients who had brain metastasis, there was no significant difference in prevalence of seizure before versus after LMD diagnosis suggesting that LMD does not significantly increase the risk of seizure compared to brain metastasis alone. A multivariate analysis revealed that while males trended toward inferior survival, only performance status and treatment with systemic chemotherapy showed a significant association with survival. Median survival time of patients after LMD diagnosis was four months. Conclusion: The prevalence of seizure in LMD patients is 22%. There were no statistically significant predisposing factors to seizure development. ECOG and use of systemic chemotherapy were found to be significant prognostic factors.

KW - Anti-epileptic drugs

KW - Leptomeningeal carcinomatosis

KW - Leptomeningeal disease

KW - Seizure

UR - http://www.scopus.com/inward/record.url?scp=85066468742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066468742&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2019.05.032

DO - 10.1016/j.jns.2019.05.032

M3 - Article

VL - 403

SP - 19

EP - 23

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

ER -